Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Abstract: The present invention is directed to a multilayered fabric comprising a first absorbable nonwoven fabric and a second absorbable woven or knitted fabric.

Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Abstract: The present invention is directed to a hemostatic wound dressing that utilizes a fibrous, fabric substrate made from carboxylic-oxidized cellulose and containing a first surface and a second surface opposing the first surface, the fabric having flexibility, strength and porosity effective for use as a hemostat; and further having a porous, polymeric matrix substantially homogeneously distributed on the first and second surfaces and through the fabric, the porous, polymeric matrix being made of a biocompatible, water-soluble or water-swellable cellulose polymer, wherein prior to distribution of the polymeric matrix on and through the fabric, the fabric contains about 3 percent by weight or more of water-soluble oligosaccharides.

Abstract: The present invention is directed to wound dressings that contain a fabric made from biocompatible polymeric fibers and having flexibility, strength and porosity effective for use as a hemostat, and a porous, polymeric matrix prepared from a biocompatible, water-soluble or water-swellable polymer dispersed through the fabric; and to methods of making such wound dressings.

Abstract: The present invention is directed to hemostatic wound dressings containing a fabric made from biocompatible, aldehyde-modified polysaccharide fibers; and a porous, polymeric matrix made from a biocompatible, water-soluble or water-swellable polymer, dispersed at least partially through the fabric, to methods of making such wound dressings and to methods of providing hemostasis to a wound.

Abstract: The present invention is directed to hemostatic wound dressings that contain a substrate for contacting a wound, wherein the substrate includes a wound-contacting surface and is fabricated at least in part from a biocompatible aldehyde-modified polysaccharide having covalently conjugated there with a hemostatic agent, and to methods of providing hemostasis to a wound that include applying the wound dressing described herein to a wound.

Abstract: The present invention is directed to a hemostatic wound dressing that utilizes a fibrous, fabric substrate made from carboxylic-oxidized cellulose and containing a first surface and a second surface opposing the first surface, the fabric having flexibility, strength and porosity effective for use as a hemostat; and further having a porous, polymeric matrix substantially homogeneously distributed on the first and second surfaces and through the fabric, the porous, polymeric matrix being made of a biocompatible, water-soluble or water-swellable cellulose polymer, wherein prior to distribution of the polymeric matrix on and through the fabric, the fabric contains about 3 percent by weight or more of water-soluble oligosaccharides.

Abstract: The present invention is directed to wound dressings that contain a fabric made from biocompatible polymeric fibers and having flexibility, strength and porosity effective for use as a hemostat, and a porous, polymeric matrix prepared from a biocompatible, water-soluble or water-swellable polymer dispersed through the fabric; and to methods of making such wound dressings.

Abstract: An activated partial thromboplastin time (APTT) test is described which employs fresh, whole blood that has not been anticoagulated. The method employs a disposable cuvette having specific reagents placed therein. A sample of whole blood is introduced into the cuvette which is drawn into at least one conduit by a pneumatic pump. Initially, the calcium in the sample is chelated at a first reaction site in the conduit, and thereafter is moved through the conduit to a second reaction site where the sample is coagulated by an APTT reagent. After a predetermined incubation time, the sample is moved to a third reaction site where it is recalcified. Clotting time is measured from the time that the sample is recalcified to the time that clot formation is visibly detected.

Abstract: A method for preparation of an air-dried prothrombin time (PT) reagent which uses a recombinant protein and synthetic phospholipids is described. The source for the recombinant protein is rabbit brain, and the phospholipids employed are palmitoyloleoylphosphatidylcholine (POPC) and palmitoyloleoylphosphatidylserine (POPS). The particular formulation buffer used to dilute the lipidated tissue factor provides a reagent that is dried without lyophilization and remains stable for at least 2 weeks at 37 C. A method for preparing the improved PT reagent and a method of using the reagent to analyze blood PT is also provided.